INTRAVENOUS ADMINISTRATION OF RECOMBINANT TISSUE-PLASMINOGEN ACTIVATOR - OPTIMIZING THE RATE OF CORONARY THROMBOLYSIS

被引:2
|
作者
PREWITT, RM [1 ]
GU, SA [1 ]
SCHICK, U [1 ]
DUCAS, J [1 ]
机构
[1] UNIV MANITOBA, DEPT MED, WINNIPEG, MB, CANADA
关键词
DOSING; RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR; THROMBOLYSIS;
D O I
10.1378/chest.107.4.1146
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Although many studies have confirmed the efficacy of thrombolytic therapy in treatment of acute myocardial infarction, few studies have been designed to determine which dose regimen optimizes the rate of coronary thrombolysis. This study was designed to compare the efficacy of coronary thrombolysis obtained with intravenous administration of three dose regimens of recombinant tissue plasminogen activator (rtPA), The same total dose was administered as a bolus, over 30 min, or over 90 min. A canine model was employed. Coronary thrombosis was induced by injection of radioactive blood clot through a catheter placed in the left anterior descending coronary artery. Subsequently, 18 dogs were randomized into 3 groups of 6 dogs each. In group 1 dogs, 0.5 mg/kg of rtPA was administered intravenously as a bolus; in the group 2 dogs, rtPA was administered intravenously over 30 min (rtPA(30)); in the group 3 dogs, the drug was administered over 90 min (rtPA(90)). Coronary thrombolysis was assessed with a gamma camera. While at 100 min, the extent of clot lysis was similar between groups, 15 and 30 min after the start of rtPA administration, coronary thrombolysis was significantly less in the rtPA(90) group. These results indicate that for a given total dose of rtPA, the rate of intravenous administration may significantly affect the rate of coronary thrombolysis.
引用
收藏
页码:1146 / 1151
页数:6
相关论文
共 50 条
  • [21] Thrombolysis with Systemic Recombinant Tissue Plasminogen Activator in Children: A Multicenter Retrospective Study
    Zengin, Emine
    Sarper, Nazan
    Erdem, Arzu Yazal
    Al, Isik Odaman
    Evim, Melike Sezgin
    Yarali, Nese
    Belen, Burcu
    Akcay, Arzu
    Yildirim, Aysen Turedi
    Karapinar, Tuba Hilkay
    Gunes, Adalet Meral
    Gelen, Sema Aylan
    Oren, Hale
    Olcay, Lale
    Baytan, Birol
    Gulen, Huseyin
    Ozturk, Gulyuz
    Orhan, Mehmet Fatih
    Oymak, Yesim
    Akpinar, Sibel
    Tufekci, Ozlem
    Albayrak, Meryem
    Gunen, Burcak Tatli
    Canpolat, Aylin
    Ozbek, Namik
    TURKISH JOURNAL OF HEMATOLOGY, 2021, 38 (04) : 294 - 305
  • [22] The use of intravenous recombinant tissue plasminogen activator in acute ischemic stroke
    Kahn, JH
    Viereck, J
    Kase, C
    Jeerakathil, T
    Romero, R
    Mehta, SD
    Kociol, R
    Babikian, V
    JOURNAL OF EMERGENCY MEDICINE, 2005, 29 (03): : 273 - 277
  • [23] Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI
    Schellinger, PD
    Jansen, O
    Fiebach, JB
    Heiland, S
    Steiner, T
    Schwab, SF
    Pohlers, O
    Ryssel, H
    Sartor, K
    Hacke, W
    STROKE, 2000, 31 (06) : 1318 - 1328
  • [24] Intravenous thrombolysis in German stroke units before and after regulatory approval of recombinant tissue plasminogen activator
    Weimar, C.
    Kraywinkel, K.
    Maschke, M.
    Diener, H. -C.
    CEREBROVASCULAR DISEASES, 2006, 22 (5-6) : 429 - 431
  • [25] Addressing the Role of Intravenous Tissue-Plasminogen Activator in Patients with Large Vessel Occlusions
    Zussman, Benjamin
    Weiner, Gregory
    Ducruet, Andrew
    NEUROSURGERY, 2018, 82 (05) : E109 - E110
  • [26] Thrombolysis with recombinant tissue plasminogen activator and tirofiban in stroke - Preliminary observations
    Seitz, RJ
    Hamzavi, M
    Junghans, U
    Ringleb, PA
    Schranz, C
    Siebler, M
    STROKE, 2003, 34 (08) : 1932 - 1935
  • [27] THE ROLE OF TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR IN FAILURE OF THROMBOLYTIC THERAPY WITH RECOMBINANT TISSUE-PLASMINOGEN ACTIVATOR
    HUBER, K
    BECKMANN, R
    RAUSCHA, F
    PROBST, P
    KAINDL, F
    BINDER, BR
    ZEITSCHRIFT FUR KARDIOLOGIE, 1993, 82 : 195 - 200
  • [28] Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA)
    Eissa, A.
    Krass, I.
    Bajorek, B. V.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (06) : 620 - 629
  • [29] CORONARY THROMBOLYSIS WITH DESMODUS SALIVARY PLASMINOGEN-ACTIVATOR IN DOGS - FAST AND PERSISTENT RECANALIZATION BY INTRAVENOUS BOLUS ADMINISTRATION
    WITT, W
    MAASS, B
    BALDUS, B
    HILDEBRAND, M
    DONNER, P
    SCHLEUNING, WD
    CIRCULATION, 1994, 90 (01) : 421 - 426
  • [30] THROMBOLYTIC RETREATMENT WITH TISSUE-PLASMINOGEN ACTIVATOR FOR THREATENED REINFARCTION AND THROMBOTIC CORONARY REOCCLUSION
    BECKER, RC
    CLINICAL CARDIOLOGY, 1994, 17 (01) : 3 - 13